News
Amgen’s second quarter results outpaced Wall Street’s expectations, with management emphasizing strong demand for its ...
Erythroid cell patterns in neoplasms show distinct genomic profile and poor venetoclax response, new research suggests.
An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...
Earnings season slows this week, with investors waiting on NVIDIA’s earnings on August 27. Retail sales and inflation ...
For developers, OpenAI claims GPT-5 is its most powerful coding model to date, outperforming GPT-o3 in benchmarks and ...
5d
Medpage Today on MSNKRAS Inhibitor Reduces Progression Risk in Pretreated Lung Cancer
The objective response rate (ORR) was 32% with adagrasib versus 9% with docetaxel (OR 4.68, 95% CI 2.56-8.56, P <0.0001), ...
Strand Therapeutics announced on Thursday that it landed a $153 million Series B funding led by Kinnevik. The company’s ...
Amgen Inc. (NASDAQ:AMGN) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Amgen Inc. (NASDAQ:AMGN) reported ...
The Irish Times has teamed up with Amgen Irish Open to give one lucky subscriber the chance to win two Saturday tickets.
Clinical trial tech outfit Medidata has elevated a new strategy leader from within. | Clinical trial tech outfit Medidata has elevated a new strategy leader from within. Industry veteran Lisa ...
5h
TipRanks on MSNAmgen’s Pediatric SHPT Study: A Potential Game-Changer for Etelcalcetide
Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is currently conducting a Phase 3 study titled Phase 3, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results